cxcl12 neutralizing antibody  (Bio X Cell)

Journal: Materials Today Bio

Article Title: Orchestrating the immuno-chondrogenic microenvironment via a bio-inorganic hybrid microsphere system for tendon-to-bone healing

doi: 10.1016/j.mtbio.2026.102851

Figure Lengend Snippet: ZIF-8/sEVs alleviate the inhibitory effects of the M1 M ϕ -mediated inflammatory microenvironment on BMSC migration and chondrogenic differentiation. A) Representative immunofluorescence images of the chemotaxis-associated proteins CXCL12 (green) and CXCR4 (red) in BMSCs cultured under different conditioned media. Nuclei were stained with DAPI (blue). B) Representative optical microscopy images of the scratch wound healing assay at 0 h and 24 h to assess the migratory capacity of BMSCs. C, D) Semi-quantitative analysis of the relative fluorescence intensity of CXCL12 and CXCR4 (C) and the wound healing ratio (D), indicating that ZIF-8/sEVs restore migration inhibited by M1 CM. E–G) Representative immunofluorescence staining of key chondrogenic markers in BMSCs, including (E) Type II Collagen (COL II, red), (F) Aggrecan (red), and (G) Sox-9 (red). The cytoskeleton was stained with Phalloidin (green) and nuclei with DAPI (blue). H–J) Semi-quantitative analysis of the relative fluorescence intensity for (H) COL II, (I) Aggrecan, and (J) Sox-9. M1 CM: M1 M ϕ conditioned media. n = 3. ∗∗p < 0.01, ∗∗∗p < 0.001, ns: p-value with no significance. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Antibodies against HSP70, CD9, CD81, Calnexin, iNOS, CD206, TNF-α, IL-10, CD29, CD90, CD68, CXCL12, CXCR4, COL II, Aggrecan, Sox-9, PI3K, p-PI3K, AKT, p-AKT, and GAPDH were purchased from Abcam (UK), Cell Signaling Technology (USA), Servicebio (Wuhan, China), Abclonal (Wuhan, China), Biolegend (Beijing, China), or Proteintech (Wuhan, China) (detailed information listed in ).

Techniques: Migration, Immunofluorescence, Chemotaxis Assay, Cell Culture, Staining, Microscopy, Wound Healing Assay, Fluorescence

Journal: Breast Cancer Research : BCR

Article Title: CXCL12/ZNF503/GATA3/MMP1 axis promotes tumor progression and metastasis of triple-negative breast cancer

doi: 10.1186/s13058-026-02248-1

Figure Lengend Snippet: CXCL12 promotes TNBC cells progression through ZNF503/GATA3. A , B CCK-8 assay for the proliferation of TNBC cells. BT-549 ( A ) and MM231 ( B ) cells were treated with CXCL12 (10 µg/ml,1:100). Data are represented as mean ± SEM. P value by Two-way ANOVA. C , D Transwell assay for the migration and invasion capabilities of BT-549 ( C ) and MM231 ( D ) cells with CXCL12 treatment. Scale bar, 5 μm. Data are represented as mean ± SEM. P value by unpaired two-tailed Student’s t test. E , F BT-549 and MM231 cells infected with control or ZNF503 shRNAs treated with or without CXCL12 were subjected to Western blotting using whole-cell lysates with ZNF503 and GATA3 antibodies. P value by unpaired two-tailed Student’s t test. G , H CCK-8 assay showed the cell viability of 4 groups. Data are represented as mean ± SEM. P value by Two-way ANOVA. I , J Transwell assay indicated the migration and invasion abilities of 4 groups. Scale bar, 5 μm. Data are represented as mean ± SEM. P value by unpaired two-tailed Student’s t test. ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001

Article Snippet: The slices were incubated with primary antibodies, including ZNF503 (Sigma, 1:800), GATA3 (Abcam, 1:800), CXCL12 (Servicebio,1:800), E-Cadherin (Servicebio,1:800), Vimentin (Servicebio,1:800), and MMP1(Servicebio,1:800), followed by secondary antibodies and DAB colorimetric solution.

Techniques: CCK-8 Assay, Transwell Assay, Migration, Two Tailed Test, Infection, Control, Western Blot

Journal: Breast Cancer Research : BCR

Article Title: CXCL12/ZNF503/GATA3/MMP1 axis promotes tumor progression and metastasis of triple-negative breast cancer

doi: 10.1186/s13058-026-02248-1

Figure Lengend Snippet: CXCL12 regulates ZNF503/GATA3 expression via the PI3K/Akt/NF-κB signaling pathway. A , B BT-549 ( A ) and MM231( B ) cells with or without CXCL12 or/and Dactolisib (Dac) were subjected to Western blotting with indicated antibodies. BT-549 and MM231 cells were treated with CXCL12 for 3 days, and Dac (500 µg/µl, 1:1000) for 2 days. P value by unpaired two-tailed Student’s t test. C The motif of NF-κB binding sites. D The schematic diagram of wild-type (ZNF503-WT) and mutant-type (ZNF503-MUT) vector. E Relative luciferase activity in HEK-293T cells transfected with control and NF-κB-overexpressing vector. Data are represented as mean ± SEM. P value by unpaired two-tailed Student’s t test. F ChIP assay to confirm the binding of NF-κB to the promoter of ZNF503 . Data are represented as mean ± SEM. P value by unpaired two-tailed Student’s t test. G Western blotting analysis for the protein expression levels of NF-κB and ZNF503 in MM231 cells transfected with control and NF-κB-overexpressing vector. P value by unpaired two-tailed Student’s t test. ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001

Article Snippet: The slices were incubated with primary antibodies, including ZNF503 (Sigma, 1:800), GATA3 (Abcam, 1:800), CXCL12 (Servicebio,1:800), E-Cadherin (Servicebio,1:800), Vimentin (Servicebio,1:800), and MMP1(Servicebio,1:800), followed by secondary antibodies and DAB colorimetric solution.

Techniques: Expressing, Western Blot, Two Tailed Test, Binding Assay, Mutagenesis, Plasmid Preparation, Luciferase, Activity Assay, Transfection, Control

Journal: Breast Cancer Research : BCR

Article Title: CXCL12/ZNF503/GATA3/MMP1 axis promotes tumor progression and metastasis of triple-negative breast cancer

doi: 10.1186/s13058-026-02248-1

Figure Lengend Snippet: MMP1 is identified as a downstream molecule of CXCL12/ZNF503/GATA3. A , B RNA-Seq analysis was conducted to identify DEGs regulated by ZNF503 ( A ) and GATA3 ( B ), with results presented in a volcano plot. C-D The top 20 terms in CC category of GO analysis regulated by ZNF503 ( C ) and GATA3 ( D ). E , F GSEA showing enrichment of the EMT pathway regulated by ZNF503 ( E ) and GATA3 ( F ). G , H Heatmaps showing EMT-related genes regulated by ZNF503 ( G ) and GATA3 ( H ). I IF assay illustrated the expression and localization of MMP1 in the indicated cells. Scale bar, 50 μm. P value by unpaired two-tailed Student’s t test. J MM231 cells lysates were subjected to Western blotting with the MMP1 and other indicated antibodies. MM231 cells were transfected with vector or ZNF503 vector, vector or GATA3 vector. P value by unpaired two-tailed Student’s t test. K MM231 cells infected with control or ZNF503 shRNAs treated with or without CXCL12 were subjected to Western blotting using whole-cell lysates with ZNF503, GATA3 and MMP1 antibodies. P value by unpaired two-tailed Student’s t test. L The motif of GATA3 binding sites. M ChIP assay to confirm the binding of GATA3 to the promoter of MMP1. Data are represented as mean ± SEM. P value by One-way ANOVA. ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001

Article Snippet: The slices were incubated with primary antibodies, including ZNF503 (Sigma, 1:800), GATA3 (Abcam, 1:800), CXCL12 (Servicebio,1:800), E-Cadherin (Servicebio,1:800), Vimentin (Servicebio,1:800), and MMP1(Servicebio,1:800), followed by secondary antibodies and DAB colorimetric solution.

Techniques: RNA Sequencing, Expressing, Two Tailed Test, Western Blot, Transfection, Plasmid Preparation, Infection, Control, Binding Assay

Journal: Breast Cancer Research : BCR

Article Title: CXCL12/ZNF503/GATA3/MMP1 axis promotes tumor progression and metastasis of triple-negative breast cancer

doi: 10.1186/s13058-026-02248-1

Figure Lengend Snippet: The CXCL12/ZNF503/GATA3/MMP1 axis promotes TNBC growth and metastasis in vivo. A Representative Images of TNBC tumor in BALB/c mice. Transplanted xenografts derived from cells with shNC/shZNF503 (above) and Vector/ZNF503 (below) were established in BALB/c nude mice ( n = 5). B Tumor growth curves in BALB/c mice after ZNF503 knockdown (left) or overexpression (right). Data are represented as mean ± SD ( n = 5). P value by Two-way ANOVA. C , D Representative IHC staining for GATA3, MMP1, E-Cadherin and Vimentin of the indicated tumor tissues. Scale bar, 20 μm. P value by unpaired two-tailed Student’s t test. E Photomicrographs of HE staining in the lung of vector control and ZNF503-overexpressing mice ( n = 3). Scale bar, 50 μm. F The number of lung metastatic foci in mice. Data are represented as mean ± SD ( n = 3). P value by unpaired two-tailed Student’s t test. G Representative IHC staining of lung metastatic foci. Scale bar, 50 μm. P value by unpaired two-tailed Student’s t test. H The schematic delineation of different strategies used in the in vivo studies. Fourteen days after tail vein injection of shNC/shZNF503 MM231 cells, 150 µl of CXCL12 (10 µg/ml) or an equal volume of saline was administered once every seven days, for a total of five injections. I Live fluorescence imaging of distant metastatic sites in NOD-SCID mice ( n = 4). The excitation and emission wavelength: GFP-465–520 nm. P value by unpaired two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001

Article Snippet: The slices were incubated with primary antibodies, including ZNF503 (Sigma, 1:800), GATA3 (Abcam, 1:800), CXCL12 (Servicebio,1:800), E-Cadherin (Servicebio,1:800), Vimentin (Servicebio,1:800), and MMP1(Servicebio,1:800), followed by secondary antibodies and DAB colorimetric solution.

Techniques: In Vivo, Derivative Assay, Plasmid Preparation, Knockdown, Over Expression, Immunohistochemistry, Two Tailed Test, Staining, Control, Injection, Saline, Fluorescence, Imaging

Journal: Breast Cancer Research : BCR

Article Title: CXCL12/ZNF503/GATA3/MMP1 axis promotes tumor progression and metastasis of triple-negative breast cancer

doi: 10.1186/s13058-026-02248-1

Figure Lengend Snippet: The CXCL12/ZNF503/GATA3/MMP1 signature serves as a potential biomarker for TNBC prognosis. A The mRNA expression levels of CXCL12, ZNF503, GATA3, and MMP1 in TNBC patients ( n = 138) and non-TNBC ( n = 839) patients. mRNA expression data derived from TCGA and clinical data came from UCSC Xena. Data are represented as mean ± SD. P value by unpaired two-tailed Student’s t test. B , C The survival curves of patients based on the integrated model in TNBC ( n = 138; low: 113; high: 25) and non-TNBC ( n = 839; low: 633; high: 206) patients. Data analyzed by log-rank test. D ROC curve analysis of combined model in TNBC and non-TNBC patients. E The mechanism of the CXCL12/ZNF503/GATA3/MMP1 axis in TNBC. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001

Article Snippet: The slices were incubated with primary antibodies, including ZNF503 (Sigma, 1:800), GATA3 (Abcam, 1:800), CXCL12 (Servicebio,1:800), E-Cadherin (Servicebio,1:800), Vimentin (Servicebio,1:800), and MMP1(Servicebio,1:800), followed by secondary antibodies and DAB colorimetric solution.

Techniques: Biomarker Discovery, Expressing, Derivative Assay, Two Tailed Test

Journal: Nature Cell Biology

Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

doi: 10.1038/s41556-026-01885-0

Figure Lengend Snippet: a . Representative images of MC38-OVA (left) and tumour growth (right) in C57BL/6J mice ( n = 5). b . Representative images of CT26 tumours (left) and tumour growth (right) in BALB/c mice ( n = 5). c . Schematic diagram illustrating the working principle of ATS-GNP adipocytolysis. ATS-GNP, containing a CaCO 3 core, is receptor-mediated for endocytosis. Upon reaching the acidic environment, ATS-GNP releases CO 2 gas, disrupting the adipose cell membrane. d . Tumour growth of MC38 tumours in C57BL/6J, BALB/c-Nude (left), and NSG (right) mice ( n = 5). e . Representative images of E0771 tumours at day 16 of the experiment in C57BL/6J mice following removal of PAT ( n = 5). f . Tumour weights of E0771 tumours at day 16 in C57BL/6J mice with the removal of PAT ( n = 5). g . Representative flow cytometry plots of CD45 + cells gated on live cells in MC38-OVA tumours. h . Violin plots showing the expression of CXCR7 across all cell types in CRC patients, analysed using the Kruskal-Wallis test. i . Editing strategy for constructing Cxcl12 fl/fl cKO mouse. j . Experimental design for constructing Control and Cxcl12 fl/fl cKO mice bearing MC38-OVA tumours near PAT. k . Western blot analysis for verifying the knockout efficiency of Cxcl12 in PAT of Control mice and Cxcl12 fl/fl cKO mice. l . RT-qPCR analysis for verifying the Cxcl12 knockout efficiency in liver, spleen, uterus, and tumour tissues from Control mice and Cxcl12 fl/fl cKO mice ( n = 6). Data represent ≥ 3 independent experiments. P -values were calculated using two-way ANOVA with Tukey’s correction for multiple comparisons ( a -right, b -right, and d ), two-way ANOVA with Bonferroni’s correction for multiple comparisons ( f ), or a two-sided, unpaired Student’s t -test ( l ). Graphs display mean ± SD ( a , b , d , f , l ). Panels created with BioRender : c , i and j , Huaiqiang, J. https://biorender.com/cy7rgjm (2026).

Article Snippet: For drug treatment, a CXCL12 neutralizing antibody (Merck Millipore) and an anti-mouse PD-1 antibody (Bio X Cell) were administered via intraperitoneal injection.

Techniques: Membrane, Flow Cytometry, Expressing, Control, Western Blot, Knock-Out, Quantitative RT-PCR

Journal: Nature Cell Biology

Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

doi: 10.1038/s41556-026-01885-0

Figure Lengend Snippet: a , Cell–cell communication analysis based on ligand–receptor interactions (top six) between stromal cells and lymphocytes in tVAT (left) and a comparison between tVAT, dVAT and tumour (right). b , Marked CXCL12–CXCR4 interactions among CD8 + T cells, CD4 + T cells, B cells, plasma cells and stromal cell populations in tVAT, dVAT and tumour. The width of the lines represents the probability of communication. c , Violin plots showing the expression of CXCL12 (top) and CXCR4 (bottom) across all cell types in patients with CRC. d , Violin plots comparing the expression of CXCL12 in dVAT versus tVAT (top) and tumour versus tVAT (bottom) in patients with CRC, analysed using a two-sided Wilcoxon test. e , Experimental design for the PAT C57BL/6J mouse model treated with IgG or anti-CXCL12 antibody (left), and representative MC38 tumour images at day 16 of the experiment (right) ( n = 5). f , Tumour growth (left) and tumour weights (right) of MC38 tumours at day 16 of the experiment in C57BL/6J mice ( n = 5). g , Representative MC38 tumour images (left) and tumour growth (right) of experiments in control and Cxcl12 fl/fl cKO mice ( n = 6). h , Tumour weights of MC38 tumours in control and Cxcl12 fl/fl cKO mice at day 16 of the experiment ( n = 6). i , Flow cytometry analysis of the infiltration of various CXCR4 + immune cells in MC38 tumours in Control and Cxcl12 fl/fl cKO mice ( n = 6). j , Schematic diagram of the chemotaxis assay using T cells as ‘sensors’ and conditional medium as a ‘sink’ (left), and the aggregated trajectories of control or CXCL12-induced T cells migrating for 1 h (right). k , Quantitative analysis of CXCR4 + CD45.1 + T cells in MC38 tumours with and without removal of PAT or contralateral inguinal adipose tissue (control) by flow cytometry ( n = 5). Data represent ≥3 independent experiments. Statistical significance was assessed by a two-sided permutation test ( a ), two-sided unpaired Student’s t -test ( f right, h and i ), one-way analysis of variance (ANOVA) with Tukey’s correction for multiple comparisons ( k right) or two-way ANOVA ( f left and g right). Graphs display mean ± s.d. ( f – i , k ). Panels created with BioRender : e and k , Huaiqiang, J. https://biorender.com/ovq2e39 (2026).

Article Snippet: For drug treatment, a CXCL12 neutralizing antibody (Merck Millipore) and an anti-mouse PD-1 antibody (Bio X Cell) were administered via intraperitoneal injection.

Techniques: Comparison, Clinical Proteomics, Expressing, Control, Flow Cytometry, Chemotaxis Assay

Journal: Nature Cell Biology

Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

doi: 10.1038/s41556-026-01885-0

Figure Lengend Snippet: a . UMAP plot of VAT-associated stromal cells in tVAT and dVAT from CRC patients. The 8 clusters, labelled by inferred cell types, are denoted by colour. b . Dot plot showing RNA expression of marker genes used to define pAC, adCAF, and APC subclusters. Circle size represents the log-normalized P -value, while colour intensity indicates the log-transformed mean expression of marker genes. c . Sorting strategy for isolating adCAFs from mouse PAT by flow cytometry. d . RNA sequencing analysis of adCAF markers in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 4). Statistical significance was assessed using a two-sided, unpaired Student’s t -test. e . RNA sequencing analysis of adipogenesis markers in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 4). Statistical significance was assessed using a two-sided, unpaired Student’s t -test. f . Representative images of the morphology of sorted adCAF-enriched stromal cells and non-adCAF stromal cells. Scale bar = 500 μm. g . Cross-tissue interactions analysis based on ligand-receptor pairs between adCAFs and tumour cells (left) and a comparison between tVAT and dVAT (right). A two-sided permutation test was used to determine the significance of pathways. h . Western blot analysis of CXCL12 protein expression in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 3). The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median) for ( d - e ).

Article Snippet: For drug treatment, a CXCL12 neutralizing antibody (Merck Millipore) and an anti-mouse PD-1 antibody (Bio X Cell) were administered via intraperitoneal injection.

Techniques: RNA Expression, Marker, Transformation Assay, Expressing, Flow Cytometry, RNA Sequencing, Comparison, Western Blot, Whisker Assay

Journal: Nature Cell Biology

Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

doi: 10.1038/s41556-026-01885-0

Figure Lengend Snippet: a , UMAP of all stromal cells in tVAT, dVAT, tumour and normal from patients with CRC, with ten clusters labelled by inferred cell types. Major lineages included ASCs, pACs, CAFs, pericytes (PCs) and mesothelial cells (Mesos). b , Heatmap displaying the distribution of eight stromal cell subtypes across different tissue types. c , UMAP of eight subsets of VAT-associated stromal cells in tVAT and dVAT from patients with CRC, including ASCs, pACs and adCAFs. d , Beeswarm plot showing the distribution and abundance of VAT-associated stromal cell types in Nhoods between tVAT and dVAT. e , Stack plot displaying the abundance of the eight VAT-associated stromal cell subsets in dVAT and tVAT. f , Heatmap showing the RNA expression of various marker genes in VAT-associated stromal cell types, including ASC/pAC markers, CAF markers, cytokines and stromal markers. g , Representative multiplex immunofluorescence images showing the presence of adCAFs in tVAT samples from patients with CRC. Scale bar, 10 μm. DAPI, 4,6-diamidino-2-phenylindole. h , Relative expression levels of multiple cytokines and protumoural factors in adCAF-enriched stromal cells ( n = 4) and non-adCAF stromal cells ( n = 4) derived from the PAT of mice xenograft models. The data are presented as a box-and-whisker graph (bounds of box show first to third quartile, bottom and top line show minimum to maximum and the central line shows the median). i , Cell–cell communication analysis based on ligand–receptor pairs (top six) between adCAFs and lymphocytes in tVAT (left) and a comparison between tVAT and dVAT (right). j , RT–qPCR (left) and ELISA (right) detecting the RNA expression and protein secretion of CXCL12 in sorted adCAF-enriched stromal cells and non-adCAF stromal cells from PAT of mice. Data represent ≥3 independent experiments. All data are shown as mean ± s.d. and statistical significance was assessed by a two-sided, unpaired Wilcoxon test ( h ), two-sided permutation test ( i ) and Student’s t -test ( j ).

Article Snippet: For drug treatment, a CXCL12 neutralizing antibody (Merck Millipore) and an anti-mouse PD-1 antibody (Bio X Cell) were administered via intraperitoneal injection.

Techniques: RNA Expression, Marker, Multiplex Assay, Immunofluorescence, Expressing, Derivative Assay, Whisker Assay, Comparison, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

Journal: Nature Cell Biology

Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

doi: 10.1038/s41556-026-01885-0

Figure Lengend Snippet: a . UMAP of all cells in tVAT and dVAT from 5 CRC patients, with 16 clusters labelled by inferred cell types. Major lineages included various immunocytes, VAT-associated stromal cells, adipocytes (ACs), endothelial cells (ECs), pericytes (PCs) and mesothelial cells (Mesos). b . Heatmap of representative marker genes across all cell populations. c . UMAP of 6 subsets of ACs in tVAT and dVAT from 5 CRC patients. d . Beeswarm plot showing the distribution and abundance of ACs in Nhoods between tVAT and dVAT. e . Box plot to compare the abundance of ACs in dVAT ( n = 5) and tVAT ( n = 5). P -values were calculated using a two-side Wilcoxon test. f . Cell-cell communication analysis based on ligand-receptor interactions (top 3) between CD8 + T cells and adipocytes, and between CD8 + T cells and VAT-associated stromal cells in tVAT. A two-sided permutation test was used to determine the significance of pathways. Only significant ligand-receptor pairs ( P < 0.05) are shown. Dot size encodes the interaction score, and colour scale indicates the communication probability. g . Violin plots showing the expression of CXCL12, VAT-associated markers, and CAF-associated markers in adipocytes and VAT-associated stromal cells from CRC patients. h . UMAP of 8 subsets of VAT-associated stromal cells in tVAT and dVAT from 5 CRC patients, including APCs, pACs and adipocyte-derived cancer-associated fibroasts (adCAFs). The 8 clusters, labelled by inferred cell types, are denoted by colour. i . Beeswarm plot showing the distribution and abundance of VAT-associated stromal cell types in Nhoods between tVAT ( n = 5) and dVAT ( n = 5). j . Box plot to compare the abundance of VAT-associated stromal cells in dVAT and tVAT. P -values were calculated using a two-side Wilcoxon test. k . Heatmap showing the RNA expression patterns of representative marker genes across all cell populations, including CAF markers, stromal markers, APC/pAC markers, white/brown/beige fat markers, and cytokines and growth markers. The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median) for ( e , j ).

Article Snippet: For drug treatment, a CXCL12 neutralizing antibody (Merck Millipore) and an anti-mouse PD-1 antibody (Bio X Cell) were administered via intraperitoneal injection.

Techniques: Marker, Expressing, Derivative Assay, RNA Expression, Whisker Assay

Journal: Nature Cell Biology

Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

doi: 10.1038/s41556-026-01885-0

Figure Lengend Snippet: a , Experimental design for constructing Control and Mdk DTR cKO mice bearing MC38 tumours near PAT, followed by αPD-1 therapy. b , c , Representative MC38 tumour images ( b ), tumour weights ( c left) and tumour growth ( c right) in control and Mdk DTR cKO mice treated with IgG or anti-PD-1 ( n = 6). d , Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells, CXCR4 + immunocytes, CXCR4 + T cell, CXCR4 + CD4 + T cell, CXCR4 + CD8 + T cell and CXCR4 + tumour-specific T cell in MC38-OVA tumours from the four treatment groups ( n = 6). e , f , Representative MC38 tumour images ( e ) and tumour weights ( f ) of the experiment in mice treated with anti-CXCL12 and/or anti-PD-1 ( n = 5). g , Representative MRI image of CRC tumour and corresponding tVAT area region of CR and non-CR patients pre- and post-immuno-chemoradiotherapy. The yellow area represents the tVAT area, whereas the red area denotes the tumour region. Note that the mass visible in the intestinal lumen (top right) is faecal material. h , Pre-treatment tVAT area difference based on 3D Slicer between CR ( n = 30) and non-CR ( n = 37) patients. The data are presented as a box-and-whisker graph (bounds of box show first to third quartile, bottom and top line show minimum to maximum and the central line shows the median). i , ROC plot of response predicting ability of pre-treatment PAT area in immuno-chemoradiotherapy of proficient mismatch repair patients with CRC, compared with conventional indexes, including CPS, TPS, CEA and CA199 ( n = 67) with optimal cutoff. j , Comparison of pCR ratio in tVAT high and low group according to the optimal cutoff. k , Graphical abstract depicting how tumours reshape the stromal environment in tVAT and how tVAT competes for immunocytes from the tumour to promote immune escape. Data represent ≥3 independent experiments. Statistical significance was assessed using a two-sided, unpaired Student’s t -test ( d , h ), one-way ANOVA with Tukey’s correction for multiple comparisons ( c left, f ) or two-way ANOVA with Tukey’s correction for multiple comparisons ( c right). Graphs display mean ± s.d. ( c , d , f , h ). Panels created with BioRender : a and k , Huaiqiang, J. https://biorender.com/e5jwcye (2026).

Article Snippet: For drug treatment, a CXCL12 neutralizing antibody (Merck Millipore) and an anti-mouse PD-1 antibody (Bio X Cell) were administered via intraperitoneal injection.

Techniques: Control, Flow Cytometry, Whisker Assay, Comparison

Journal: Nature Cell Biology

Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

doi: 10.1038/s41556-026-01885-0

Figure Lengend Snippet: a . Editing strategy for constructing Mdk DTR mouse. b . Flow cytometry representative plots and bar graphs for verifying the elimination efficiency of adCAFs (FAP + PDGFRB + MDK + stromal cells) in PAT of Control mice and Mdk DTR cKO mice. c . Experimental design for combination therapy with αCXCL12 and αPD-1 in mice bearing MC38-OVA tumours near PAT. d . MC38 tumour weights of the experiment in mice treated with αCXCL12 and/or αPD-1 ( n = 6). e . Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells in MC38-OVA tumours from the 4 treatment groups ( n = 6). f . Flow cytometry analysis of the infiltration of CXCR4 + immunocytes, including CXCR4 + T cell, CXCR4 + CD4 + T cell and CXCR4 + CD8 + T cell in MC38-OVA tumours from the 4 treatment groups ( n = 6). g . Boxplot of difference of tVAT area in CR and non-CR patients with T3 or T4 stage separately. The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median). h . ROC plot of prediction ability of tVAT area in patients with T3 or T4 stage separately. Data represent ≥ 3 independent experiments. P -values were calculated using a two-sided, unpaired Student’s t -test ( b , e - g ) and two-way ANOVA with Tukey’s correction for multiple comparisons ( d ). Graphs display mean ± SD ( b , d , e - g ). Panels created with BioRender : a and c , Huaiqiang, J. https://biorender.com/33r2gmm (2026).

Article Snippet: For drug treatment, a CXCL12 neutralizing antibody (Merck Millipore) and an anti-mouse PD-1 antibody (Bio X Cell) were administered via intraperitoneal injection.

Techniques: Flow Cytometry, Control, Whisker Assay

Journal: Nature Cell Biology

Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

doi: 10.1038/s41556-026-01885-0

Figure Lengend Snippet: a . Experimental design for combination therapy with AMD3100 and αPD-1 in mice bearing MC38-OVA tumours near subcutaneous PAT. b . Representative MC38 tumour images of the mice treated with AMD3100 and/or αPD-1 ( n = 5). c . Representative MC38 tumour weights of the mice treated with AMD3100 and/or αPD-1 ( n = 5). d . Representative MC38 tumour growth of the mice treated with AMD3100 and/or αPD-1 ( n = 5). e . Representative MC38 tumour images in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). f . Representative MC38 tumour weights in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). g . Representative MC38 Bioluminescence Images in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). h . Representative MC38 tumour images in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). i . Representative MC38 tumour weights in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). j . Representative MC38 Bioluminescence Images in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). k . Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells in MC38-OVA tumours from 4 treatment groups ( n = 5). l . Flow cytometry analysis of the infiltration of CXCR4 + immunocytes, including CXCR4 + T cell, CXCR4 + CD4 + T cell and CXCR4 + CD8 + T cell in MC38-OVA tumours from 4 treatment groups ( n = 5). Data represent ≥ 3 independent experiments. P -values were calculated using a two-sided, unpaired Student’s t -test ( c , f , i , k , l ) and two-way ANOVA with Tukey’s correction for multiple comparisons ( d ). Graphs display mean ± SD ( c - d , f , i , k - l ). Panel created with BioRender : a , Huaiqiang, J. https://biorender.com/wbcolts (2026).

Article Snippet: For drug treatment, a CXCL12 neutralizing antibody (Merck Millipore) and an anti-mouse PD-1 antibody (Bio X Cell) were administered via intraperitoneal injection.

Techniques: Flow Cytometry